Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 4
2008 3
2009 6
2010 6
2011 3
2012 2
2014 7
2015 9
2016 11
2017 13
2018 20
2019 27
2020 20
2021 32
2022 27
2023 26
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

207 results

Results by year

Filters applied: . Clear all
Page 1
Human Herpesvirus-6 Reactivation and Disease Are Infrequent in Chimeric Antigen Receptor T-cell Therapy Recipients.
Kampouri E, Krantz EM, Xie H, Ibrahimi SS, Kiem ES, Sekhon MK, Liang EC, Cowan AJ, Portuguese AJ, Green DJ, Albittar A, Huang JJ, Gauthier J, Pérez-Osorio AC, Jerome KR, Zerr D, Boeckh MJ, Hill JA. Kampouri E, et al. Among authors: hill ja. Blood. 2024 Apr 18:blood.2024024145. doi: 10.1182/blood.2024024145. Online ahead of print. Blood. 2024. PMID: 38635788
Defining and Grading Infections in Clinical Trials Involving Hematopoietic Cell Transplantation: A Report From the BMT CTN Infectious Disease Technical Committee.
Shahid Z, Etra AM, Levine JE, Riches ML, Baluch A, Hill JA, Nakamura R, Toor AA, Ustun C, Young JH, Perales MA, Epstein DJ, Murthy HS. Shahid Z, et al. Among authors: hill ja. Transplant Cell Ther. 2024 May;30(5):540.e1-540.e13. doi: 10.1016/j.jtct.2024.03.001. Epub 2024 Mar 6. Transplant Cell Ther. 2024. PMID: 38458478
SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101).
Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Howard DS, Ibrahim U, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA. Hill JA, et al. medRxiv [Preprint]. 2024 Jan 25:2024.01.24.24301058. doi: 10.1101/2024.01.24.24301058. medRxiv. 2024. PMID: 38343800 Free PMC article. Preprint.
A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant.
Nakamura R, La Rosa C, Yang D, Hill JA, Rashidi A, Choe H, Zhou Q, Lingaraju CR, Kaltcheva T, Longmate J, Drake J, Slape C, Duarte L, Al Malki MM, Pullarkat VA, Aribi A, Devine S, Verneris MR, Miller JS, Forman SJ, Aldoss I, Diamond DJ. Nakamura R, et al. Among authors: hill ja. Haematologica. 2024 Feb 8. doi: 10.3324/haematol.2023.284544. Online ahead of print. Haematologica. 2024. PMID: 38328852 Free article.
207 results